Cargando…

Does Siponimod Exert Direct Effects in the Central Nervous System?

The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes. Different sphingosine 1-phosphate receptor subtypes are expressed in the brain and spinal cord, and their...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kipp, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463861/ https://www.ncbi.nlm.nih.gov/pubmed/32722245 http://dx.doi.org/10.3390/cells9081771

Ejemplares similares

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights
por: Bigaud, Marc, et al.
Publicado: (2021)

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis
por: Weier, Alicia, et al.
Publicado: (2022)

What Guides Peripheral Immune Cells into the Central Nervous System?
por: Greiner, Theresa, et al.
Publicado: (2021)

Siponimod for multiple sclerosis
Publicado: (2021)

Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5
por: Behrangi, Newshan, et al.
Publicado: (2022)

Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma
por: Basavarajappa, Devaraj, et al.
Publicado: (2022)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
por: Bigaud, Marc, et al.
Publicado: (2023)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Immunotherapy for cancer in the central nervous system: Current and future directions
por: Binder, David C., et al.
Publicado: (2015)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System
por: Harrison-Brown, Meredith, et al.
Publicado: (2016)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

PGRMC1 Exerts Its Function of Anti-Influenza Virus in the Central Nervous System
por: Huang, Kun, et al.
Publicado: (2021)

Effects of growth hormone in the central nervous system
por: Wasinski, Frederick, et al.
Publicado: (2019)

Schwann cell remyelination of the central nervous system: why does it happen and what are the benefits?
por: Chen, Civia Z., et al.
Publicado: (2021)

Vascularisation of the central nervous system
por: Tata, Mathew, et al.
Publicado: (2015)

Mucormycosis of the Central Nervous System
por: Chikley, Amanda, et al.
Publicado: (2019)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury
por: Basavarajappa, Devaraj, et al.
Publicado: (2023)

Influence Exerted by Anæsthetics on the Brain and Nervous System
Publicado: (1868)

Propionate exerts neuroprotective and neuroregenerative effects in the peripheral nervous system
por: Grüter, Thomas, et al.
Publicado: (2023)

Effects of Brazilian scorpion venoms on the central nervous system
por: Nencioni, Ana Leonor Abrahão, et al.
Publicado: (2018)

Beneficial Effects of Capsaicin in Disorders of the Central Nervous System
por: Pasierski, Michał, et al.
Publicado: (2022)

Coronaviruses and the central nervous system
por: Morgello, Susan
Publicado: (2020)

The Central Nervous System of Vertebrates
por: Nicholls, J. G.
Publicado: (1967)

The Central Nervous System and Behavior
por: May, Mark A.
Publicado: (1959)

Structure of the Central Nervous System
Publicado: (1891)

Does misonidazole enhance radiation injury to the central nervous system?
por: Field, S. B., et al.
Publicado: (1981)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6avgf5a108lmm8eg8rp75inu85